Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: oxycodone

California Doctor Gets 30 Years to Life in Landmark Overdose Case

Steve Gorman  |  February 6, 2016

LOS ANGELES (Reuters)—A Southern California doctor was sentenced to 30 years to life in prison on Friday for over-prescribing drugs that caused the fatal overdose of three patients in a murder case capped by the first conviction of its kind in the U.S. The case against Dr. Hsiu Ying “Lisa” Tseng, 46, comes amid what…

Filed under:AnalgesicsDrug UpdatesLegal UpdatesProfessional Topics Tagged with:AddictionCDCLegalMedical MalpracticeOpioidsOverdosePrescribing Rules

U.S. Appeals Court Ruling May Clear Barrier to Generic OxyContin

Brendan Pierson  |  February 3, 2016

(Reuters)—A federal appeals court ruled Monday that four patents related to Purdue Pharma’s painkiller OxyContin are invalid, potentially bringing Teva Pharmaceutical Industries Ltd and others a step closer to introducing generic versions of the drug. Privately owned, Connecticut-based Purdue had sued Teva, Amneal Pharmaceuticals and Epic Pharma after they sought approval from the U.S. Food…

Filed under:AnalgesicsDrug Updates Tagged with:generic drugsLegalOpioidsOxycodoneOxyContinPurdue PharmaTeva Pharmaceuticals

FDA Approves New Drugs for Pain

Michele B. Kaufman, PharmD, BCGP  |  January 19, 2016

FDA Updates Belbuca, buccal-administered buprenorphine, has received U.S. Food and Drug Administration (FDA) approval for treating severe chronic pain.1 The dosage form is a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. It’s expected to be commercially available in the first quarter of 2016. Seven dosage strengths…

Filed under:AnalgesicsDrug Updates Tagged with:DrugsFDAOsteoarthritisPainrheumatologySafety

Does Methotrexate Increase Skin Cancer Risk?

Lara C. Pullen, PhD  |  November 16, 2015

A recent study connects the use of immunosuppressant and biologic agents to an increased risk of nonmelanoma skin cancer in patients being treated for RA and IBD…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Cancerinflammatory bowel diseaseMethotrexatenonmelanoma skin cancer (NMSC)Rheumatoid Arthritis (RA)rituximab

Immunotherapy May Be Effective for Some Patients with Autoimmune Cerebellar Ataxia

Will Boggs, MD  |  October 7, 2015

NEW YORK (Reuters Health)—Immunotherapy appears to yield neurological improvements in some patients with autoimmune cerebellar ataxia, especially those with nonparaneoplastic disorders, researchers report. “I was surprised that so many patients responded to immunotherapy (steroids, intravenous immunoglobulin (IVIg), and plasma exchange) and remained ambulatory,” Dr. Andrew McKeon from Mayo Clinic in Rochester, Minn., told Reuters Health…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Autoimmune Cerebellar AtaxiaAutoimmune diseaseCorticosteroidsimmunoglobulinimmunotherapyNeurologyrituximab

Biosimilar for Infliximab Launched in Europe

Michele B. Kaufman, PharmD, BCGP  |  April 1, 2015

Plus, updates on arhalofenate, ALO-02, and other rheumatology drug news, safety information

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsDrugsFDAinfliximabKaufmanrheumatologySafety

10 Tips for Opioid Prescribing

Dennis J. Boyle, MD  |  December 1, 2014

How to manage the risks when prescribing medications for patients in chronic pain

Filed under:AnalgesicsAxial SpondyloarthritisConditionsDrug UpdatesPain Syndromes Tagged with:Ankylosing SpondylitisBoyleChronic paindruginfliximabopioidPainpatient careprednisoneprescriberheumatologist

Fallout from False Assumptions in Medicine

Simon M. Helfgott, MD  |  December 1, 2014

How the lack of clear, concise data has impacted opioid prescribing for chronic pain and is clouding the issue of medical recertification

Filed under:Career DevelopmentCertificationFrom the CollegeOpinionPractice SupportProfessional TopicsQuality Assurance/ImprovementRheuminationsSpeak Out Rheum Tagged with:HelfgottMaintenance of CertificationmedicalmedicineopioidPainpatient carerheumatologist

Decernotinib, Subcutaneous Methotrexate Drug Updates, Trials, Approvals

Michele B. Kaufman, PharmD, BCGP  |  October 1, 2014

Plus, rheumatology drug news, safety updates

Filed under:ConditionsDrug UpdatesResearch RheumRheumatoid Arthritis Tagged with:drugFDAInjectionKaufmanMethotrexateResearchRheumatoid arthritisrheumatologistSafetyTofacitinib

Rheumatology Drug Updates, Trials, Safety Data

Michele B. Kaufman, PharmD, BCGP  |  May 1, 2014

Information on oral anticoagulant apixaban, apremilast for active psoriatic arthritis, hyaluronic acid and methotrexate injections, and drug safety updates rheumatologists need to know

Filed under:AnalgesicsBiologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:anti-inflammatoryapremilastBiologicsdrugMethotrexateOsteoarthritispatient careradiographRheumatoid arthritisrheumatologistrheumatologySafetyTofacitinib

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences